U.S. markets close in 2 hours 18 minutes

Virax Biolabs Group Limited (VRAX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.82-1.92 (-19.71%)
As of 01:41PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close9.74
Bid7.85 x 1200
Ask7.97 x 1100
Day's Range7.56 - 9.77
52 Week Range5.40 - 29.00
Avg. Volume7,317,815
Market Cap88.945M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for VRAX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Virax Biolabs Group Limited
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Fair Value
    Economic Moat
View more
  • Motley Fool

    Why Virax Biolabs Stock Plummeted 74% On Friday

    Shares of Virax Biolabs (NASDAQ: VRAX) dropped 74% on Friday. The biotech company, which specializes in the detection and treatment of viral diseases, just began trading on the NASDAQ on July 21 after an initial public offering (IPO).

  • GlobeNewswire

    Virax Biolabs Introduces Monkeypox and Varicella-Zoster Viruses Real-Time PCR Detection Kit

    Kits Available in July for DistributionLondon, United Kingdom, July 26, 2022 (GLOBE NEWSWIRE) -- Virax Biolabs Group Limited (“Virax” or the “Company”) (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, today launched distribution of Monkeypox and Varicella-Zoster Viruses Real Time PCR Detection Kits in response to the world’s major Monkeypox outbreak. These specialized diagnostic kits are available now in Europe and can be

  • GlobeNewswire

    Virax Biolabs Group Limited Completes Initial Public Offering; Shares Begin Trading Today on NASDAQ Capital Market as VRAX

    London, United Kingdom, July 21, 2022 (GLOBE NEWSWIRE) -- Virax Biolabs Group Limited (“Virax” or the “Company”) (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, today announced it has completed its initial public offering (IPO), and the Company’s shares began trading today on the Nasdaq Capital Market under the ticker symbol "VRAX." The company’s IPO consisted of 1,350,000 ordinary shares at a public offering price of $5.